XORTX Therapeutics Inc. (XRTX)
After hours:
| Previous Close | 2.6000 |
| Open | 2.6300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.5700 - 2.6300 |
| 52 Week Range | 1.9800 - 67.7160 |
| Volume | |
| Avg. Volume | 50,980 |
| Market Cap | 7.491M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3800 |
| Earnings Date | Aug 14, 2024 - Aug 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.12 |
- Baystreet
Stocks in play: XORTX Therapeutics Inc.
Announces that it has received TSX Venture Exchange approval to amend the terms of the balance of outstanding ...
GlobeNewswireXORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30, 2024, the Company has received TSX Venture Exchange (“TSXV”) approval to amend the terms of the balance of outstanding common share purchase warrants (“Warr
- GlobeNewswire
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of March 11, 2024, the Company has received TSX Venture Exchange approval to amend the terms of an aggregate of 1,024,099 outstanding common share purchase warrants (“Warrants”) by
